INT22030

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 1984
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 31
Total Number 32
Disease Relevance 21.83
Pain Relevance 12.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Cysltr1) plasma membrane (Cysltr1) signal transducer activity (Cysltr1)
Anatomy Link Frequency
bar 2
forebrain 2
synapse 2
respiratory 2
colon 1
Cysltr1 (Mus musculus)
Pain Link Frequency Relevance Heat
depression 747 100.00 Very High Very High Very High
long-term potentiation 263 100.00 Very High Very High Very High
antagonist 89 100.00 Very High Very High Very High
Anterior cingulate cortex 72 99.68 Very High Very High Very High
spinal dorsal horn 6 98.52 Very High Very High Very High
Hippocampus 84 97.80 Very High Very High Very High
Central grey 4 97.72 Very High Very High Very High
Inflammation 79 97.68 Very High Very High Very High
Inflammatory mediators 4 97.04 Very High Very High Very High
Glutamate receptor 214 97.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Depression 747 100.00 Very High Very High Very High
Altitude Sickness 16 99.28 Very High Very High Very High
Targeted Disruption 318 98.88 Very High Very High Very High
Hepatotoxicity 3 98.72 Very High Very High Very High
Respiratory Disease 99 98.22 Very High Very High Very High
Urological Neuroanatomy 10 97.72 Very High Very High Very High
INFLAMMATION 89 97.68 Very High Very High Very High
Hypoxia 10 97.44 Very High Very High Very High
Asthma 407 97.24 Very High Very High Very High
Nociception 36 97.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In vivo the excitatory response of the rabbit distal colon to LTD4 was abolished by pretreatment with atropine (0.1 mg/kg iv) or hexamethonium (5 mg/kg iv) or the LTD4 receptor antagonist SK&F 102922 (0.8 micrograms/kg ia).
Negative_regulation (abolished) of LTD4 in colon associated with antagonist
1) Confidence 0.39 Published 1990 Journal Am. J. Physiol. Section Abstract Doc Link 2240218 Disease Relevance 0 Pain Relevance 0.11
With 3.0 micrograms/kg of LTD4, MBF remained decreased up to 15 min after the injection.
Negative_regulation (decreased) of LTD4
2) Confidence 0.37 Published 1994 Journal Jpn. Circ. J. Section Abstract Doc Link 7967000 Disease Relevance 0 Pain Relevance 0
However, the failure of LTD4 to enhance bronchoconstriction due to ACh or vagal stimulation, together with the prevention of the interaction between LTD4 and H by capsaicin-pretreatment, suggests that the site of the interaction may be on capsaicin-sensitive afferent neurones.
Negative_regulation (failure) of LTD4 associated with qutenza
3) Confidence 0.30 Published 1984 Journal Agents Actions Section Abstract Doc Link 6085218 Disease Relevance 0 Pain Relevance 0.44
It is expected that combination of cysteinyl leukotriene receptor antagonist with cyclooxygenase inhibitor would prove to be a novel approach to treat complex inflammatory conditions.
Negative_regulation (antagonist) of leukotriene receptor associated with inflammation and antagonist
4) Confidence 0.29 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11438310 Disease Relevance 1.13 Pain Relevance 0.57
All three are specifically active against the cysteinyl leukotrienes by blocking their receptor, CysLT1.
Negative_regulation (blocking) of CysLT1
5) Confidence 0.21 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376066 Disease Relevance 0.61 Pain Relevance 0.18
The LTRAs block the CysLT1 receptor and thus block the biological action of LTC4, LTD4, and LTE4.
Negative_regulation (block) of CysLT1 receptor
6) Confidence 0.14 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.31 Pain Relevance 0.05
Most AERD patients synthesize excessive leukotrienes and severity of respiratory disease corresponds with the baseline production of leukotrienes.31,32 In addition, AERD patients express more cysteinyl LT1 receptors on their inflammatory cells.33 Aspirin and inhibitors of COX-1 divert arachidonic acid toward the lipoxygenase pathway, hence causing additional overproduction of inflammatory mediators.34 Interestingly, despite the role of leukotrienes in AERD, medications that modify this pathway, such as zileuton, a 5-lipoxygenase inhibitor, or inhibit cysteinyl leukotriene receptor (CysLT1), such as montelukast or zafirlukast, do not prevent upper airway reactions during aspirin challenges.35 Rather, CysLT1 inhibitors primarily prevent or attenuate bronchospasm.35 Studies have demonstrated that leukotriene modifier drugs positively impact treatment of AERD and, as we will discuss, also improve safety of aspirin challenges.36-38
Negative_regulation (inhibit) of cysteinyl leukotriene receptor in respiratory associated with aspirin, inflammatory mediators, inflammation, bronchospasm and respiratory disease
7) Confidence 0.13 Published 2011 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC3005316 Disease Relevance 1.05 Pain Relevance 0.36
Most AERD patients synthesize excessive leukotrienes and severity of respiratory disease corresponds with the baseline production of leukotrienes.31,32 In addition, AERD patients express more cysteinyl LT1 receptors on their inflammatory cells.33 Aspirin and inhibitors of COX-1 divert arachidonic acid toward the lipoxygenase pathway, hence causing additional overproduction of inflammatory mediators.34 Interestingly, despite the role of leukotrienes in AERD, medications that modify this pathway, such as zileuton, a 5-lipoxygenase inhibitor, or inhibit cysteinyl leukotriene receptor (CysLT1), such as montelukast or zafirlukast, do not prevent upper airway reactions during aspirin challenges.35 Rather, CysLT1 inhibitors primarily prevent or attenuate bronchospasm.35 Studies have demonstrated that leukotriene modifier drugs positively impact treatment of AERD and, as we will discuss, also improve safety of aspirin challenges.36-38
Negative_regulation (inhibit) of CysLT1 in respiratory associated with aspirin, inflammatory mediators, inflammation, bronchospasm and respiratory disease
8) Confidence 0.13 Published 2011 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC3005316 Disease Relevance 1.05 Pain Relevance 0.36
A nonselective antagonist of CysLT1 and CysLT2 and inhibitors of FLAP have been developed, but they are not yet clinically available.
Negative_regulation (antagonist) of CysLT1 associated with antagonist
9) Confidence 0.09 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.52 Pain Relevance 0.26
A 4-day course of leukotriene receptor blockade does not prevent symptoms of AMS.
Negative_regulation (blockade) of leukotriene receptor associated with altitude sickness
10) Confidence 0.07 Published 2007 Journal High Alt. Med. Biol. Section Abstract Doc Link 17584007 Disease Relevance 0.97 Pain Relevance 0.08
Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia.
Negative_regulation (blockade) of Leukotriene receptor associated with hypoxia and altitude sickness
11) Confidence 0.07 Published 2007 Journal High Alt. Med. Biol. Section Title Doc Link 17584007 Disease Relevance 0.88 Pain Relevance 0.06
The leukotriene antagonist (LTRA) Montelukast blocking the leukotriene receptor Cys-LT1 could be the rationale to treat EG with this drug[15].
Negative_regulation (blocking) of leukotriene receptor associated with antagonist
12) Confidence 0.04 Published 2005 Journal BMC Gastroenterol Section Body Doc Link PMC1187886 Disease Relevance 0.69 Pain Relevance 0.26
However, there are controversial results showing that mice with diminished LTD have normal motor learning [57], [58].
Negative_regulation (diminished) of LTD associated with depression
13) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386150 Disease Relevance 0.77 Pain Relevance 0.39
In fact, LTD was impaired in PTPMEG mutant mice [47].
Negative_regulation (impaired) of LTD associated with depression
14) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386150 Disease Relevance 0.52 Pain Relevance 0.64
When 10 mM EGTA was introduced into a PC, LTD was strongly suppressed in the wild-type mice (95.1±9.4%, n?
Negative_regulation (suppressed) of LTD associated with depression
15) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386150 Disease Relevance 0.61 Pain Relevance 0.30
In agreement with this, a larger fraction of longer pauses in Purkinje-cell activity were observed in awake behaving mice deficient in LTD.


Negative_regulation (deficient) of LTD associated with depression
16) Confidence 0.04 Published 2007 Journal Neuron Section Body Doc Link PMC1885969 Disease Relevance 0.46 Pain Relevance 0.23
The leukotriene antagonist (LTRA) Montelukast blocking the leukotriene receptor Cys-LT1 could be the rationale to treat EG with this drug[15].
Negative_regulation (blocking) of Cys-LT1 associated with antagonist
17) Confidence 0.03 Published 2005 Journal BMC Gastroenterol Section Body Doc Link PMC1187886 Disease Relevance 0.69 Pain Relevance 0.26
It has been repeatedly reported that impairment of LTD is associated with motor learning deficits [13], [52]–[54].
Negative_regulation (impairment) of LTD associated with depression
18) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386150 Disease Relevance 0.79 Pain Relevance 0.40
Long-term depression (LTD) at PF-PC synapses, motor learning and motor coordination are impaired in GluR?
Negative_regulation (depression) of LTD in synapses associated with depression and glutamate receptor
19) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386150 Disease Relevance 0.20 Pain Relevance 0.58
Our results showed that LTP but not LTD is reduced in adult hippocampal slices from neurabin KO mice.
Negative_regulation (reduced) of LTD associated with targeted disruption, depression and long-term potentiation
20) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2169299 Disease Relevance 0.78 Pain Relevance 0.49

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox